Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Bio-inspired robotic bird has stable flight in its sights
The nankeen kestrel is among the most stable fliers in the avian world. Using motion capture...
Protecting particles that carry mRNA in dry vaccine patches
Combining expertise from RMIT University, MIT and Harvard Medical School, scientists set out to...
Copper drug clears Alzheimer's proteins — lab experiments reveal
A drug that delivers copper to the brain has been found to significantly reduce Alzheimer's...
